Mgi Pharma Inc (Other) (8-K)
27 Setembro 2007 - 5:22PM
Edgar (US Regulatory)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 27, 2007
MGI PHARMA, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Minnesota
|
|
0-10736
|
|
41-1364647
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
5775 West Old Shakopee Road, Suite 100, Bloomington, Minnesota
|
|
55437
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (952) 346-4700
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
INFORMATION TO BE INCLUDED IN THE REPORT
Section 8 Other Events
Item 8.01 Other Events.
On September 27, 2007, MGI PHARMA, INC. (MGI PHARMA) issued a press release announcing that
it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for
Aquavan
®
(fospropofol disodium) Injection, an investigational drug that is being studied as a
sedative-hypnotic agent in patients undergoing brief surgical or diagnostic procedures. A copy of
the press release is attached as Exhibit 99.1 to this report and is incorporated herein by
reference.
The press release contains certain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words
such as believes, expects, anticipates, intends, will, may, should, or similar
expressions. These forward-looking statements are not guarantees of MGI PHARMAs future
performance and involve a number of risks and uncertainties that may cause actual results to differ
materially from the results discussed in these statements. Factors that might cause MGI PHARMAs
results to differ materially from those expressed or implied by such forward-looking statements
include, but are not limited to, the ability of MGI PHARMA to continue to increase sales of its
marketed products, the successful completion of clinical trials for the MGI PHARMAs other product
candidates, and other risks and uncertainties detailed from time to time in MGI PHARMAs filings
with the Securities and Exchange Commission including its most recently filed Form 10-K and Form
10-Q. MGI PHARMA undertakes no duty to update any of these forward-looking statements.
Section 9 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
|
99.1
|
|
MGI PHARMA, INC. Press Release dated September 27, 2007.
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
MGI PHARMA, INC.
|
|
Date: September 27, 2007
|
By:
|
/s/
Eric P. Loukas
|
|
|
|
Eric P. Loukas
|
|
|
|
Executive Vice President and Chief Operating
Officer
|
|
3
EXHIBIT INDEX
99.1
|
|
MGI PHARMA, INC. Press Release dated September 27, 2007.
|
4
Mgi Pharma (MM) (NASDAQ:MOGN)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Mgi Pharma (MM) (NASDAQ:MOGN)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024
Notícias em tempo-real sobre Mgi Pharma (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Mgi Pharma Inc